Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,075 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.
Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, Stiller M, Becker JC, Lennerz V, Wölfel T, Schadendorf D, Griewank K, Paschen A. Zhao F, et al. Among authors: schadendorf d. Cancer Res. 2016 Aug 1;76(15):4347-58. doi: 10.1158/0008-5472.CAN-16-0008. Epub 2016 Jun 3. Cancer Res. 2016. PMID: 27261508
Candidate genes for cross-resistance against DNA-damaging drugs.
Wittig R, Nessling M, Will RD, Mollenhauer J, Salowsky R, Münstermann E, Schick M, Helmbach H, Gschwendt B, Korn B, Kioschis P, Lichter P, Schadendorf D, Poustka A. Wittig R, et al. Among authors: schadendorf d. Cancer Res. 2002 Nov 15;62(22):6698-705. Cancer Res. 2002. PMID: 12438269
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R. Hauschild A, et al. Among authors: schadendorf d. J Clin Oncol. 2003 Aug 1;21(15):2883-8. doi: 10.1200/JCO.2003.07.116. J Clin Oncol. 2003. PMID: 12885805 Clinical Trial.
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG).
Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, Hauschild A, Schadendorf D. Zimpfer-Rechner C, et al. Among authors: schadendorf d. Melanoma Res. 2003 Oct;13(5):531-6. doi: 10.1097/00008390-200310000-00012. Melanoma Res. 2003. PMID: 14512795 Clinical Trial.
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.
Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Höglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Kärre K, Shibuya A, Carbone E, Colucci F. Lakshmikanth T, et al. Among authors: schadendorf d. J Clin Invest. 2009 May;119(5):1251-63. doi: 10.1172/JCI36022. Epub 2009 Apr 6. J Clin Invest. 2009. PMID: 19349689 Free PMC article.
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S. Paschen A, et al. Among authors: schadendorf d. Clin Cancer Res. 2009 Aug 15;15(16):5208-15. doi: 10.1158/1078-0432.CCR-09-0886. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671853
A multimarker prognostic assay for primary cutaneous melanoma.
Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J, Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller JR 3rd, Sagebiel RW. Kashani-Sabet M, et al. Among authors: schadendorf d. Clin Cancer Res. 2009 Nov 15;15(22):6987-92. doi: 10.1158/1078-0432.CCR-09-1777. Epub 2009 Nov 3. Clin Cancer Res. 2009. PMID: 19887476 Free PMC article.
1,075 results